Purpose. To evaluate the efficacy and toxicity of primary chemotherapy with the schedule E400P in the treatment of patients with early stage II (Ha and lib) and advanced seminoma of good prognosis according to the international classification (IGCCCG)
Introduction
Testicular seminoma accounts for approximately 50% of all testicular germ-cell tumours. At diagnosis, 75%-80% of patients have no detectable disease outside the testis (stage I), 20% retropentoneal, mediastinal or supraclavicular lymph nodes, and less than 5% visceral metastactic disease. However, up to 3%-20% of patients with stage I will relapse after orchiectomy followed by surveillance, radiotherapy or adjuvant chemotherapy [1] .
In 1997, the International Germ Cell Cancer Collaborative Group (IGCCCG) published a prognostic classification for patients with advanced germ-cell tumours treated with cisplatin-based chemotherapy [2] . All patients with advanced seminoma without non-pulmonary visceral metastases were included in the good-risk group. Five-year progression-free survival and overall survival were 82% and 86%, respectively Patients with nonpulmonary visceral metastases were included in the intermediate-risk group, and their five-year progressionfree survival and overall survival were 67% and 76%, respectively. No patients with advanced seminoma were classified as poor-risk. Another prognostic classification for patients with advanced seminoma, treated with chemotherapy and not previously irradiated, was recently proposed by the Medical Research Council (MRC). A prognostic model was recommended for clinical use. patients with either stage II disease or stage I1I-IV without non-pulmonary visceral metastasis and LDH <2 x N were classified as good-prognosis. Three-year progression-free survival was 94% for these patients and 56% for the poor prognosis group [3] .
Radiotherapy alone achieves cure rates of 89% in patients with retropentoneal disease smaller than 5 cm (stages Ha, lib) and it has been classically considered as the standard treatment [4, 5] . However, an increased incidence of second malignancies that arise in irradiated areas has been reported in long-term survivors [6] . Moreover, a small number of patients develop recurrences, usually outside the irradiated area, after radiotherapy [1, 5] In the last years, several studies addressed to reduce the toxicity of chemotherapy in good prognosis germcell tumours (including non-seminoma and seminoma patients) have been reported. One study showed that bleomycin could be avoided when four cycles of EP are administered, achieving similar results to the standard three cycles of BEP, but without the risk of the serious pulmonary toxicity associated with this drug [10] . Retrospective studies established that a cumulative dose of etoposide greater than 2 g/m 2 was associated with an increased risk of leukemia [11] . Some recent trials showed that regimens with doses of etoposide below this quantity are highly effective, like three cycles of BE500P [7] or four cycles of the european BE360P [12] . In addition, another study conducted by EORTC-MRC proved that the administration of BEP in three days had no detrimental effect on the effectiveness of the classic five days BEP regimen [13] We performed a multicentre study to evaluate the efficacy and toxicity of E400P regimen in patients with early stage II (Ha and lib) and advanced testicular seminoma of good prognosis according to the IGCCCG classification A main objective of this study was to determine the efficacy of primary chemotherapy in the treatment of early stage II patients, avoiding the administration of radiotherapy, and its potential complications and failures in this group of patients. The rationale for the use of E400P chemotherapy schedule, administered in both early and advanced stages, was to limit the toxicity associated with chemotherapy. This regimen combines some of the characteristics of different regimens studied in recent trials, to avoid the administration of bleomycin, to limit the cumulative dose of etoposide below 2 g/m 2 , and to administer a dose of etoposide of only 400 mg/m 2 per cycle, trying to reduce the haematologic toxicity often associated with 500 mg/m 2 regimen
Patients and methods
Between March 1994 and January 1999. 64 consecutive patients diagnosed with metastatic testicular seminoma were included in a multicentre study Mean age was 38 years (19-83), and 10 patients (16%) were more than 50 years old Forty-nine patients (77%) had advanced seminoma at diagnosis, and fifteen patients had a relapse of a previous stage I seminoma (one patient had received two courses of adjuvant carboplatin. one patient adjuvant radiotherapy and the rest were on surveillance) All patients included met the IGCCCG criteria of good prognosis, and all but two were classified as good-prognosis according to the MRC prognostic model According to the Royal Marsden staging system. 34 patients (53%) were classified as Ila-b and 30 patients (47%) as llc-IV (only I patient had a stage IV due to pulmonary metastases) Fifty-seven patients (89%) had retropentoneal metastases. (%) 21(33) 6(9 4) 2(3) 2(3) 2(3) 2(3) 1( 1 6) 0(0) other lymph-node locations were retrocrural (11%), mediastinal (9 4%), supraclavicular (5%), pelvic (2%) and inguinal (6%) There were no patients with non-pulmonary visceral metastases Eight patients (12 5%) had hydronephrosis at diagnosis Seventeen patients (27%) had LDH values greater or equal than two times the upper normal limit Human chononic gonadotropin (HCG) was elevated in 17 patients (27%) No patients had high levels of alpha-fetoprotein (AFP) at diagnosis E400P consisted of cisplatin 25 mg/m 2 /d and etoposide 100 mg/m 2 /d for four days, with adequate hydration and antiemetic therapy Cycles were administered every three weeks Prophylactic filgrastnm was administered in the following courses of chemotherapy, after an episode of neutropenia gTade 3-4 All patients were informed about fertility, and cryopreservation of semen was offered The total number of cycles administered was determined by clinical and tumour marker response Chemotherapy was stopped when a complete response was achieved, or after at least four courses of chemotherapy if the residual masses were stable and the markers were normalized Surgical resection or biopsy of residual masses was recommended when the presence of viable tumour was suspected or the size was larger than 3 cm, otherwise, patients were followed-up
The following situations were classified as treatment failures progressive disease during the chemotherapy treatment, presence of viable tumour in a residual mass after chemotherapy, regrowth of a residual mass, relapse after complete remission or unacceptable toxicity (patient or doctor criteria) Time to treatment failure (TTF) was measured from the date of the first cycle of E400P until the date in which any of those five situations was detected, and overall survival! (OS) from this same date to death or last contact Both TTF and OS were analysed according to the Kaplan-Meier method [14] Results Sixty-four patients were entered into the study. The number of cycles administered to each patient was 3 (9.5%), 4 (78%), 5 (9.5%) and 6 (3%). E400P was well tolerated (Table 1) . Most relevant grade 3-4 toxicity was neutropenia Twenty-two patients received prophylactic filgrastim during the following courses after the first episode of grade 3-4 leucopema Six patients had at least one neutropenic febrile episode. Fifty-seven patients (89%) achieved dose intensity greater or equal to 80% of the maximum possible dose intensity, and forty-three patients (67%) more than 90%. No long-term serious toxicities have been reported to date.
Response to E400P was seen in 63 out of 64 patients (98%), 44 patients with complete response (69%) and 19 patients (29%) with residual disease and negative markers after chemotherapy (4 abdominal masses and 1 pulmonary metastasis). One patient had progressive With a median follow-up of 34 months, 7 patients (11%) failed after responding to E400P at 2, 3, 5, 6, 10, 10 and 15 months (mean 7 3 months). One patient with retroperitoneal disease at diagnosis developed pulmonary metastases during the treatment, one patient had viable tumour in an abdominal residual mass, two patients had regrowth of a retroperitoneal residual mass, and three patients relapsed in retroperitoneum after a complete remission (one of them presented simultaneous lung metastases). There were no failures due to unacceptable toxicity or toxic deaths. No patients were lost to follow-up. Six patients who failed after responding to E400P received chemotherapy (cisplatin-ifosfamide containing regimens) and one patient was treated with radiotherapy. At this moment in time in the present analysis, 6 out of 7 patients are alive, 3 of them are in complete remission at 3+, 20+ and 29+ after failure, and the other 3 patients are still on treatment at 1+, 6+ and 7+ months after failure For the whole series, median time to failure has not been reached. Three-year probabilities of being free from treatment failure, and their 95% confidence intervals (CI) are 89% (95% CI: 80%-97%) for all patients, 91% (95% CI: 80%-99%) for stages Ila-b, and 87% (95% CI 74%-99%) for stages IIc-IV (Figure 1 ). An analysis of the prognostic value of different patient characteristics is shown in Table 2 Only 1 patient (stage lib) has died due to progressive disease at 25 months. Another patient with stage lid died at 38 months due to a cause unrelated to the tumour or its treatment Three patients are alive with disease and fifty-nine patients (92%) remain alive free 
Discussion
Non-localised seminoma includes a wide spectrum of disease extent. In general, retroperitoneal radiotherapy in stages Ila-b and chemotherapy in stages IIc-IV achieves a high proportion of cures. Though radiation has been traditionally recommended as standard treatment for patients with stages Ila-b, the delivery of 40 Gy to the retroperitoneum has been associated with a small, but clearly demonstrated, risk for secondary solid tumours inside the radiation fields [6, [15] [16] [17] Due to the excellent prognosis of this group, some authors have suggested the reduction of radiation doses and field sizes or the substitution of radiotherapy by primary chemotherapy in order to minimize treatment-associated toxlciry [6] . In addition, when the IGCCCG classification was published there was no distinction in terms of retroperitoneal tumour burden among the patients with difficulties in evaluating residual masses of seminoma, we preferred to use the most practical term of treatment failure to analyse our results. We found a low rate of failures after responding to E400P (7 patients, 11%). All of them occurred early in the first 15 months after the beginning of the treatment (4 out of 7 in the first 6 months). We could not identify any prognostic factor associated with a higher risk of failure, although 23% of patients with high LDH levels at diagnosis failed to respond to this treatment (Table 2 ) Thus, the value of LDH as a prognostic factor should be further considered in patients with advanced seminoma as proposed o 12 24 ae 48 eo by the MRC classification. With a median follow-up of 34 months, and only 8 Figure 2 Overall survival for the whole serie (and 95% confidence patients followed for less than 15 months, we do not intervals) expect many more failures after responding to E400P. Therefore, the three-year probability of being free from stage II. Therefore, because all cases should be classified treatment failure in our series seems to be comparable within the good-prognosis group, there is not any special with the standard treatments previously mentioned This reason to treat the patients with different approaches To statement seems to be true in both subsets of patients: our knowledge this is the first study referred to a homostage Ilab and He-IV Three-year overall survival for geneous group of patients with advanced seminoma of the whole group of patients and stages Ila-b was 97% good prognosis according to the IGCCCG classification, and 95%, respectively. We also made a separate analysis that includes a subset of patients with stages Ila-b of the 62 patients who met the MRC criteria of good treated with the same schedule of chemotherapy. Neverprognosis Their three-year probability of being free from theless, an analysis of stages Ila-b versus He-IV has treatment failure was 88% (95% CI: 80-96), and overall also been performed In addition we have included an survival 97% (95% CI: 93%-99%). The three-year proanalysis according to the MRC prognostic classification gression-free survival estimated by the MRC classificato define more precisely the value of LDH or supration was 94% for this subset of patients, diafragmatic lymph node involvement.
The role of chemotherapy for patients with stage Ila-b
Seminoma has an exquisite sensitivity to chemohas not been clearly defined. In our series, the three-year therapy. Either three courses of BEP or four courses probability of being free from failure was 90.5% and of EP can be considered as standard treatments for overall survival was 94.7%, respectively. These results advanced seminoma [1, 7, 9] . Doses ofetoposide in these are at least comparable to the 89% obtained with radiaregimens have fluctuated between 360 mg/m 2 (European tion therapy As discussed above, treatment of these regimen) and 500 mg/m 2 (American regimen) without patients with chemotherapy has some potential advanlosing any sort of activity The schedule E400P employed tages over radiotherapy approach: to decrease late in the present series is given in four days, avoids bleomymorbidity associated with radiotherapy such as peptic cin as did the standard control arm in the US trial of EP ulcer or second tumours in the irradiated field, or the versus EC [18] and in the MRC trial of EP versus singleadverse prognosis that has been associated with some agent carboplatin [19] , maintains the total dose of cisrelapses after irradiation [5] . None of our patients with platin and finally, gives etoposide at a dose in the range stage Ilab received a cumulative dose ofetoposide greater between the standard doses of 360 and 500 mgs/m 2 than 2 g/m 2 , which is the dose associated with a higher preventing the cumulative dose reaching a total greater risk of leukemia. Although, a randomized study with a than 2 g/m 2 . long follow-up would be the only way to compare the E400P was well tolerated in these populations of efficacy of both treatments, this would be very difficult patients There were no toxic deaths. Neutropenia was to carry out because of the large number of cases needed seen in a third of patients, but it was succesfully avoided to detect significant differences when the cure rates exduring the next courses by the use of filgrastim. Thus we pected are superior to 90%. were able to achieve more than 80% of the maximum
In conclusion, in our experience E400P is an active planned doses of both drugs in 89% of our patients, and safe schedule similar to the other regimens considered Other haematological and non haematological toxicities standard in patients with good prognosis advanced semiwere not relevant. After a median follow-up of 34 months, noma. The main feature of the study is the good results it is too early to analyse long-term toxicities such as obtained in stages Ila-b seminoma with this chemothermfertility or second tumours, but to date no serious late apy regimen, that could avoid the toxicity of bleomycin effects have been reported in other published series [20, and prevent some of the late morbidity associated with 21].
radiotherapy whereas the cure rates are maintained at the Response rate was high (98%) and it was at least same level It is time to accept chemotherapy as standard comparable to that achieved with E500P or BEP Due to alternative to radiotherapy in seminoma stages Ila-b.
